Under the agreement, the companies will commercialise Ruconest (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in the Republic of Korea.
Ruconest is a recombinant version of the human protein C1 inhibitor (C1INH), which is produced through Pharming’s proprietary technology.
Hyupjin will drive the regulatory approval in Korea and purchase its commercial supplies of Ruconest from Pharming at a fixed transfer price.
Hyupjin Corporation general manager Macsan Cho said: "In our continuous effort to bring the most innovative therapeutics to patients, this agreement to distribute Ruconest will now enable us to provide the Korean HAE patients access to this most innovative way to treat their disease."